Skip to main content
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. logo

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. — Investor Relations & Filings

Ticker · 2196 HKEX Manufacturing
Open in API
Filings indexed 4,426 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2196

About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

http://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven healthcare industry group operating across pharmaceuticals, medical devices, medical diagnosis, and healthcare services. The company focuses on therapeutic areas including oncology, cardiovascular, central nervous system, and metabolism, prioritizing technological advancement in small molecule development, antibody/ADC platforms, and cell therapies. Key products include Yikeda®, China's first approved CAR-T cell therapy product, and innovative biologics such as the anti-PD-1 monoclonal antibody Hanszhuang®. Fosun Pharma is a significant global health contributor via Artesun® (Artesunate injection), a WHO-recommended first-line treatment for severe malaria. The company also markets biosimilars, including Hanquyou® (Trastuzumab), which achieved dual approval in China and Europe, and distributes high-value medical devices, such as the Da Vinci surgical robot.

Recent filings

Filing Released Lang Actions
Overseas Regulatory Announcement - Announcement in Relation to the Approval for Drug Registration of a Subsidiary
Regulatory Filings
2026-04-30 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings
2026-04-30 English
2026 FIRST QUARTERLY REPORT
Regulatory Filings
2026-04-28 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 1% confidence The document is extremely short (242 characters) and solely states that an announcement has been published in the Chinese section of the website. There is no substantive report content or financial data. This matches the definition of a Report Publication Announcement (RPA): an announcement regarding the timing or publication of company reports.
2026-04-28 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 1% confidence The text is extremely brief (under 250 characters) and simply states that an announcement has been published elsewhere without including any substantive financial or corporate information. It functions as a notice that a report or announcement is available, rather than the report itself. This matches the Report Publication Announcement (RPA) category.
2026-04-28 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 1% confidence The text is extremely brief and simply notifies that an announcement has been published in another section. It does not contain any substantive report content or financial data but merely states that a document is now available elsewhere. This fits the “Report Publication Announcement” category rather than an actual report or substantive filing.
2026-04-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.